Immunologic Factors: all 3,292 studies that test it

Page 19 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.

• Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MMActive, not recruitingNCT04176718Phase 2
• Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:CompletedNCT04175522Phase 2
• A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With PlasmacytomaActive, not recruitingNCT04174196Phase 2
• Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell LymphomaActive, not recruitingNCT04161248Early Phase 1
• Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaTerminatedNCT04156828Phase 1
• Cryoablation for the Treatment of Metastatic CancerActive, not recruitingNCT04150939Not applicable
• NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaCompletedNCT04136756Phase 1
• A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma PatientsActive, not recruitingNCT04124497Phase 2
• Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)CompletedNCT04121403Phase 3
• R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II StutyStatus unknownNCT04120350Phase 1/2
• Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)CompletedNCT04114188Phase 2
• Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell LymphomaCompletedNCT04113226Phase 2
• Ixazomib + Pomalidomide + Dexamethasone In MMActive, not recruitingNCT04094961Phase 1/2
• PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBVStatus unknownNCT04084626Phase 3
• Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic AnemiaCompletedNCT04083014Phase 2
• S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationActive, not recruitingNCT04071457Phase 3
• Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM PatientsCompletedNCT04065789Phase 2
• Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMMCompletedNCT04052880Phase 2
• DNA Vaccination Against NeuroblastomaStatus unknownNCT04049864Early Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT04045028Phase 1
• A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)CompletedNCT04035135Phase 1
• IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific AntibodiesCompletedNCT04033276Phase 4
• MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI PatientsCompletedNCT04032626Phase 2
• Biomarker Guided Treatment in DLBCLStatus unknownNCT04025593Phase 2
• Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCLCompletedNCT04022005Phase 2
• Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMActive, not recruitingNCT04009109Phase 2
• Rituximab for HTLV-1-associated MyelopathyStatus unknownNCT04004819Phase 2
• Transplant Antibody-Mediated Rejection: Guiding Effective TreatmentsTerminatedNCT03994783Phase 3
• Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)CompletedNCT03983031Phase 1
• Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular LymphomaActive, not recruitingNCT03980171Phase 1/2
• RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MSActive, not recruitingNCT03979456Phase 3
• RItuximab From the FIRst Episode of Idiopathic Nephrotic SyndromeStatus unknownNCT03970577Phase 2
• A Study to Desensitize Allergic Reactions to Treatments for Blood DisordersCompletedNCT03959358Phase 2
• TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Phase 3
• Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCLStatus unknownNCT03949062Phase 2
• Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and LymphomaCompletedNCT03934814Phase 1
• Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic PolyangiitisCompletedNCT03920722Phase 3
• Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat LymphomaCompletedNCT03900377Phase 1/2
• A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's SyndromeActive, not recruitingNCT03899337Phase 2
• Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT03892421Phase 1/2
• Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCLStatus unknownNCT03891355Phase 2
• Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT03879694Phase 1
• The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 AutoantibodiesCompletedNCT03864185Phase 2
• TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Phase 2
• Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic SclerosisActive, not recruitingNCT03844061Phase 2
• Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaWithdrawnNCT03841565Phase 2
• DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
• Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or ImmunotherapyActive, not recruitingNCT03835520Not applicable
• Autologous Transplant To End NMO Spectrum DisorderWithdrawnNCT03829566Phase 2/3
• STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMAActive, not recruitingNCT03829371Phase 4
• Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic OsteosarcomaWithdrawnNCT03811886Phase 1/2
• Study to Demonstrate Clinical Benefit of Lenalidomide and DexamethasoneActive, not recruitingNCT03809780Phase 2
• The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir AlafenamideTerminatedNCT03804372Phase 2
• Personalized Medicine for Membranous NephropathyCompletedNCT03804359Phase 2
• Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell LymphomaCompletedNCT03798314Phase 1
• Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCLStatus unknownNCT03795571Phase 1
• Biomarker Assessments of Leukine During Treatment of Parkinson's DiseaseCompletedNCT03790670Phase 1
• Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" TrialCompletedNCT03790293Phase 3
• Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney TransplantationStatus unknownNCT03789006Phase 4
• A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose TherapyWithdrawnNCT03785184Phase 2
• A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic CancersTerminatedNCT03783403Phase 1
• MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell OriginStatus unknownNCT03778619Phase 1/2
• Study of Cosibelimab in Subjects With Relapsed or Refractory LymphomaTerminatedNCT03778073Phase 1
• Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)Status unknownNCT03777085Phase 3
• PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-TransplantCompletedNCT03763643Early Phase 1
• Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple MyelomaActive, not recruitingNCT03756896Phase 2
• Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person SyndromeWithdrawnNCT03749096Phase 3
• Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM PatientsTerminatedNCT03733691Phase 2
• Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedNCT03732703Phase 1/2
• Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell LymphomaStatus unknownNCT03730740Phase 2
• Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT03720041Phase 3
• Multi-Center Study of GSK2857916 in Combination With Pomalidomide and DexActive, not recruitingNCT03715478Phase 1/2
• R2 in the Treatment of Follicular LymphomaStatus unknownNCT03715309Phase 2
• Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)CompletedNCT03703167Phase 1
• Lenalidomide in Anti-MAG Neuropathy: Phase 1b StudyTerminatedNCT03701711Phase 1
• Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia AStatus unknownNCT03700229Phase 2
• Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory NeuropathiesCompletedNCT03700138Phase 3
• MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone LymphomasActive, not recruitingNCT03697512Phase 2
• Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin LymphomaStatus unknownNCT03688451Phase 2
• A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT03670901Phase 3
• A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma PatientsTerminatedNCT03670888Phase 1
• Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple MyelomaStatus unknownNCT03669445Phase 2
• Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple MyelomaWithdrawnNCT03657420Phase 1
• Personalized Therapies in Inflammatory Complex DiseaseCompletedNCT03651518Phase 2
• Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03651128Phase 3
• Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma PatientsActive, not recruitingNCT03643133Phase 2
• Efficacy of First Line B-RI for Treatment Naive Waldenström's MacroglobulinemiaActive, not recruitingNCT03620903Phase 2
• An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma PatientsActive, not recruitingNCT03606577Phase 2
• Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MMStatus unknownNCT03605056Phase 2
• Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationWithdrawnNCT03602898Phase 2
• Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in MexicansStatus unknownNCT03601624Phase 2
• Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in ChinaStatus unknownNCT03598725Phase 4
• Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell LeukemiaWithdrawnNCT03591744Phase 1
• Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple MyelomaTerminatedNCT03590652Phase 2
• A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic SettingCompletedNCT03589105Phase 4
• Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)TerminatedNCT03578198Phase 2
• Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic SyndromeSuspendedNCT03560011Phase 2/3
• Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System LymphomaTerminatedNCT03558750Phase 1
• A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell TransplantationActive, not recruitingNCT03556332Phase 2
• CPI Combination Therapy for Autoimmune EncephalitisCompletedNCT03542279Not applicable

← Immunologic Factors overview